Riskpilot← Back to searchSign inGet full accessUCB Pharma Oy Finland
OYActiveY-tunnus 0114461-2Bertel Jungin Aukio 5Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1960— employees
Revenue 2024
EUR 23,8M
+11% vs 2023
EBITDA margin
4.2%
+5% vs 2023
Equity ratio
38.2%
Financial strength
Net profit 2024
EUR 771K
+4% vs 2023
| Revenue | EUR 23,8M | +11% |
| EBITDA | EUR 993K | +5% |
| Net profit | EUR 771K | +4% |
| Total assets | EUR 11,9M | +10% |
| Equity | EUR 4,5M | +1% |
| Employees | — | — |
Legal name
UCB Pharma Oy Finland
Y-tunnus number
0114461-2
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
19. helmikuuta 1960
Share capital
EUR 8 409
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Toimitusjohtaja yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on harjoittaa lääketukkukauppatoimintaa; lääkkeiden, rohdosvalmisteiden, luontaistuotteiden, ravintolisien, kosmetiikkatuotteiden, terveydenhuollon tarvikkeiden ja laitteiden sekä vapaiden kauppatavaroiden tuontia, kauppaa ja agentuuritoimintaa ja myynnin edistämistä.
Address
Bertel Jungin Aukio 5
Phone
+358925144221
Email
etunimi.sukunimi@ucb.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 24 326 | 22 595 | 21 127 | 21 408 | 23 826 |
| Staff expenses | −1 859 | −2 382 | −3 927 | −2 924 | −3 645 |
| EBITDA | 1 006 | 933 | 965 | 948 | 993 |
| Depreciation & amort. | — | −0 | −1 | −1 | −0 |
| EBIT | 1 006 | 933 | 964 | 947 | 992 |
| Net financials | −35 | −45 | −31 | −4 | −6 |
| Profit before tax | 972 | 887 | 933 | 944 | 987 |
| Tax | 199 | 183 | 194 | 202 | 215 |
| Net profit | 773 | 705 | 739 | 742 | 771 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 12 441 | 13 069 | 11 818 | 10 829 | 11 887 |
| Equity | 3 565 | 4 270 | 4 509 | 4 511 | 4 542 |
| Long-term debt | 202 | 155 | 166 | 0 | 0 |
| Short-term debt | 8 674 | 8 645 | 7 143 | 6 317 | 7 345 |
| Total debt | 8 876 | 8 799 | 7 309 | 6 317 | 7 345 |
EBITDA margin
4.2%
This company
15.8%
Market median
-73% vs market
20202024
Equity ratio
38.2%
This company
38.2%
Market median
+0% vs market
20202024
Return on equity
17.0%
This company
18.4%
Market median
+8% vs market
20202024
Net profit margin
3.2%
This company
8.1%
Market median
-60% vs market
20202024
Asset turnover
2.00×
This company
1.12×
Market median
+79% vs market
20202024
Debt / equity
1.62×
This company
0.62×
Market median
-161% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ML Person with significant control | Person with significant control | 2019 |
| Former (4) | ||
MP | Audit | 2021 – 2023 |
PO Chief Executive Officer | Chief Executive Officer | 2019 – 2019 |
PJ Person with significant control | Person with significant control | 2013 – 2019 |
MA | Audit | 2010 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2025 | |
| Board of Directors | 2025 | |
| Chairperson | 2025 | |
| Former (5) | ||
| Board of Directors | 2018 – 2021 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2018 – 2019 | |
| Board of Directors | 2019 – 2025 | |
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of UCB Pharma Oy Finland also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mika Petteri Järvinen | Audit | 0 companies |
| Per Ove Jonas Berg | Chief Executive Officer | 0 companies |
| Pekka Juhani Aroviita | Person with significant control | 0 companies |
| Martin Andreas Grandell | Audit | 0 companies |
| Maarit Linnea Taiha | Person with significant control | 0 companies |
| Guy Florimond M. Van den Dorpe | Board of Directors | 0 companies |
| Christina Dyreborg Jeppesen | Board of Directors | 0 companies |
| Ilaria Villa | Board of Directors | 0 companies |
| Francois Joseph Gerald Vanier | Board of Directors | 0 companies |
| Afshin Mag. Risseh | Board of Directors | 0 companies |
| Jaana Mattila | Board of Directors | 0 companies |
| Ana Isabel Infante Gonzalez De La Aleja | Board of Directors | 0 companies |
| Laura Ann Byram | Chairperson | 0 companies |